< Back

Stella Blackburn

Leader background:
Dr Stella Blackburn. MB BS, MA, MSc, FRCP(Ed), FISPE, FFPM, DLSHTM, Dip Pharm Med. VP, Global Head of Early Access & Risk Management, Real World Evidence Solutions at IQVIA. Stella studied medicine at Cambridge and Guys and worked in hospital medicine before joining the pharmaceutical industry. She has worked in pharmacovigilance and pharmacoepidemiology for 30+ years: in industry (11+ years) as a regulator (nearly 17 years) and CRO (4+ years). She has an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine and co-developed their course in Pharmacovigilance and Pharmacoepidemiology. In 1997 she joined the European Medicines Agency (EMA). Stella developed EU strategy and policy on risk management, writing the EU guidelines on this topic and was part of the core team implementing the 2010 PhV legislation. She was on original steering group developing ENCEPP and was the Alternate Co-ordinator, and a scientific work package leader, of IMI PROTECT. She currently advises companies on EU strategy and risk management and has a special interest in rare diseases. Stella is a Fellow of the International Society of Pharmacoepidemiology (ISPE), the Royal College of Physicians of Edinburgh and the Faculty of Pharmaceutical Medicine. She is a past President of ISPE and an Honorary Associate Professor at the LSHTM and Visiting Scientist at MIT.
How RWE is generated – studies, databases, methods and analytics
    Level: Area:
    Code: Sym7.2 Duration: 00:45:00
Registries as a source of RWE
    Level: Area:
    Code: Sym7.3 Duration: 00:35:00
PANEL DISCUSSION – Regulatory and decision-maker position on RWE
    Level: Area: Symposium
    Code: Sym7.4 Duration: 00:55:00